Oncolytics Biotech® Inc. is a clinical-stage biotechnology company developing innovative immunotherapy solutions for cancer treatment. The company’s lead product candidate, pelareorep, is an intravenously delivered oncolytic virus designed to selectively replicate in cancer cells while stimulating anti-tumor immune responses.

The company’s development strategy emphasizes combination therapies that enhance the effectiveness of existing cancer treatments, including immune checkpoint inhibitors and chemotherapy.

• Clinical-stage biotechnology company focused on cancer immunotherapy
• Lead product candidate pelareorep evaluated across multiple oncology indications
• Strategy centered on combination therapies with existing cancer treatments
• Clinical programs conducted with global research partners
• Publicly traded on NASDAQ under the ticker ONCY

• Exposure to oncology immunotherapy via a differentiated oncolytic virus platform
• Clinical-stage profile with value creation driven by trial milestones
• Potential upside through partnerships and regulatory progress
• Ongoing capital market engagement supports long-term growth initiatives
• May suit portfolios seeking asymmetric risk–reward biotechnology exposure